Period,symbol,NAV,sharesOutstanding,researchDevelopment,effectOfAccountingCharges,incomeBeforeTax,minorityInterest,netIncome,sellingGeneralAdministrative,grossProfit,ebit,operatingIncome,otherOperatingExpenses,interestExpense,extraordinaryItems,nonRecurring,otherItems,incomeTaxExpense,totalRevenue,totalOperatingExpenses,costOfRevenue,totalOtherIncomeExpenseNet,discontinuedOperations,netIncomeFromContinuingOps,netIncomeApplicableToCommonShares,intangibleAssets,capitalSurplus,totalLiab,totalStockholderEquity,otherCurrentLiab,totalAssets,commonStock,otherCurrentAssets,retainedEarnings,cash,totalCurrentLiabilities,shortLongTermDebt,propertyPlantEquipment,totalCurrentAssets,inventory,accountsPayable,otherLiab,longTermDebt,changeToLiabilities,totalCashflowsFromInvestingActivities,netBorrowings,totalCashFromFinancingActivities,changeToOperatingActivities,issuanceOfStock,changeInCash,totalCashFromOperatingActivities,depreciation,changeToInventory,otherCashflowsFromFinancingActivities,changeToNetincome,capitalExpenditures,repurchaseOfStock,dividendsPaid,WC,language,region,quoteType,triggerable,quoteSourceName,currency,market,bookValue,fiftyDayAverage,fiftyDayAverageChange,fiftyDayAverageChangePercent,twoHundredDayAverage,twoHundredDayAverageChange,twoHundredDayAverageChangePercent,marketCap,forwardPE,priceToBook,sourceInterval,exchangeTimezoneName,exchangeTimezoneShortName,gmtOffSetMilliseconds,esgPopulated,tradeable,regularMarketPrice,regularMarketTime,regularMarketChange,regularMarketOpen,regularMarketDayHigh,regularMarketDayLow,regularMarketVolume,marketState,exchange,priceHint,regularMarketChangePercent,regularMarketDayRange,regularMarketPreviousClose,bid,ask,bidSize,askSize,messageBoardId,fullExchangeName,longName,financialCurrency,averageDailyVolume3Month,averageDailyVolume10Day,fiftyTwoWeekLowChange,fiftyTwoWeekLowChangePercent,fiftyTwoWeekRange,fiftyTwoWeekHighChange,fiftyTwoWeekHighChangePercent,fiftyTwoWeekLow,fiftyTwoWeekHigh,epsTrailingTwelveMonths,epsForward,exchangeDataDelayedBy,shortName,Beta (5Y Monthly),52-Week Change 3,S&P500 52-Week Change 3,52 Week High 3,52 Week Low 3,50-Day Moving Average 3,200-Day Moving Average 3,Avg Vol (3 month) 3,Avg Vol (10 day) 3,Shares Outstanding 5,Implied Shares Outstanding 6,Float,% Held by Insiders 1,% Held by Institutions 1,Shares Short 4,Short Ratio 4,Short % of Float 4,Short % of Shares Outstanding 4,Shares Short (prior month ) 4,Forward Annual Dividend Rate 4,Forward Annual Dividend Yield 4,Trailing Annual Dividend Rate 3,Trailing Annual Dividend Yield 3,5 Year Average Dividend Yield 4,Payout Ratio 4,Dividend Date 3,Ex-Dividend Date 4,Last Split Factor 2,Last Split Date 3,Fiscal Year Ends,Most Recent Quarter (mrq),Profit Margin,Operating Margin (ttm),Return on Assets (ttm),Return on Equity (ttm),Revenue (ttm),Revenue Per Share (ttm),Quarterly Revenue Growth (yoy),Gross Profit (ttm),EBITDA,Net Income Avi to Common (ttm),Diluted EPS (ttm),Quarterly Earnings Growth (yoy),Total Cash (mrq),Total Cash Per Share (mrq),Total Debt (mrq),Total Debt/Equity (mrq),Current Ratio (mrq),Book Value Per Share (mrq),Operating Cash Flow (ttm),Levered Free Cash Flow (ttm),index,zip,sector,fullTimeEmployees,longBusinessSummary,city,phone,state,compensationAsOfEpochDate,country,website,maxAge,address1,fax,industry,address2
t0,CYDY,-22671000.0,612875008,14369000,,-44891000,,-44891000,8992000,0,-23636000,-23636000,,-2525000,,,,0,0,23636000,0,-21255000,,-44891000,-44891000,1653000.0,489650000.0,153098000.0,-21018000.0,2647000.0,132080000.0,626000.0,1543000.0,-511294000.0,33943000.0,152546000.0,62747000.0,846000.0,129581000.0,93479000.0,65897000.0,,,406000.0,-22000.0,50000000.0,52480000.0,866000.0,791000.0,19652000.0,-32806000.0,275000.0,59000.0,1689000.0,9602000.0,-22000.0,,,-22965000.0,en-US,US,EQUITY,False,Delayed Quote,USD,us_market,-0.026,1.4719445,-0.091944456,-0.062464625,2.4202898,-1.0402898,-0.42982033,845767488,-7.6666665,-53.076923,15,America/New_York,EDT,-14400000,False,False,1.38,1630439981,0.049999952,1.28,1.34,1.28,1050119,REGULAR,PNK,4,3.759395,1.28 - 1.34,1.28,0.0,0.0,0,0,finmb_10039157,Other OTC,CytoDyn Inc.,USD,2096629,1783950,0.120000005,0.0952381,1.26 - 7.4,-6.02,-0.8135135,1.26,7.4,-0.294,-0.18,0,CYTODYN INC,-0.56,,,7.4,1.26,1.4719,2.4203,2.1M,1.78M,612.88M,,553.54M,12.75%,0.14%,,,,,,,,,,,0.00%,,,,,"May 30, 2021","May 30, 2021",0.00%,0.00%,-64.72%,,,,,,-92.75M,-154.67M,-0.2940,,33.94M,0.05,63.47M,,0.85,-0.03,-117.57M,-76.66M,Value,98660,Healthcare,24,"CytoDyn Inc. operates as a late-stage biotechnology company. The company focuses on developing treatments for multiple therapeutic indications based on leronlimab, a novel humanized monoclonal antibody targeting the CCR5 receptor. Its Leronlimab is in a class of therapeutic monoclonal antibodies designed to address unmet medical needs in the areas of human immunodeficiency virus (HIV), cancer, immunology, and novel coronavirus disease (COVID-19). The company has completed a Phase 2b pivotal trial using leronlimab in combination with antiretroviral therapies in HIV-infected treatment-experienced patients, as well as completed a Phase 2b/3 investigative trial with leronlimab as a once-weekly monotherapy for HIV-infected patients. It is also conducting a Phase 1b/2 clinical trial with leronlimab in metastatic triple-negative breast cancer. The company was formerly known as RexRay Corporation. CytoDyn Inc. was incorporated in 2002 and is based in Vancouver, Washington.",Vancouver,360 980 8524,WA,1609372800,United States,http://www.cytodyn.com,86400,1111 Main Street,360 799 5954,Biotechnology,Suite 660
t-1,CYDY,-17710000.0,612875008,12323000,,-43985000,,-43985000,7902000,0,-20736000,-20736000,,-5576000,,,,0,0,20736000,0,-23249000,,-43985000,-43985000,1915000.0,449579000.0,129449000.0,-15795000.0,2227000.0,113654000.0,609000.0,1819000.0,-465983000.0,14291000.0,128861000.0,37976000.0,884000.0,110855000.0,93537000.0,72509000.0,,,-8926000.0,-23000.0,50000000.0,8555000.0,-710000.0,5219000.0,-15116000.0,-23648000.0,511000.0,5533000.0,3336000.0,23751000.0,-23000.0,,,-18006000.0,en-US,US,EQUITY,False,Delayed Quote,USD,us_market,-0.026,1.4719445,-0.091944456,-0.062464625,2.4202898,-1.0402898,-0.42982033,845767488,-7.6666665,-53.076923,15,America/New_York,EDT,-14400000,False,False,1.38,1630439981,0.049999952,1.28,1.34,1.28,1050119,REGULAR,PNK,4,3.759395,1.28 - 1.34,1.28,0.0,0.0,0,0,finmb_10039157,Other OTC,CytoDyn Inc.,USD,2096629,1783950,0.120000005,0.0952381,1.26 - 7.4,-6.02,-0.8135135,1.26,7.4,-0.294,-0.18,0,CYTODYN INC,-0.56,,,7.4,1.26,1.4719,2.4203,2.1M,1.78M,612.88M,,553.54M,12.75%,0.14%,,,,,,,,,,,0.00%,,,,,"May 30, 2021","May 30, 2021",0.00%,0.00%,-64.72%,,,,,,-92.75M,-154.67M,-0.2940,,33.94M,0.05,63.47M,,0.85,-0.03,-117.57M,-76.66M,Value,98660,Healthcare,24,"CytoDyn Inc. operates as a late-stage biotechnology company. The company focuses on developing treatments for multiple therapeutic indications based on leronlimab, a novel humanized monoclonal antibody targeting the CCR5 receptor. Its Leronlimab is in a class of therapeutic monoclonal antibodies designed to address unmet medical needs in the areas of human immunodeficiency virus (HIV), cancer, immunology, and novel coronavirus disease (COVID-19). The company has completed a Phase 2b pivotal trial using leronlimab in combination with antiretroviral therapies in HIV-infected treatment-experienced patients, as well as completed a Phase 2b/3 investigative trial with leronlimab as a once-weekly monotherapy for HIV-infected patients. It is also conducting a Phase 1b/2 clinical trial with leronlimab in metastatic triple-negative breast cancer. The company was formerly known as RexRay Corporation. CytoDyn Inc. was incorporated in 2002 and is based in Vancouver, Washington.",Vancouver,360 980 8524,WA,1609372800,United States,http://www.cytodyn.com,86400,1111 Main Street,360 799 5954,Biotechnology,Suite 660
t-2,CYDY,-18996000.0,612875008,16446000,,-34966000,,-34966000,7551000,0,-24503000,-24503000,,-6294000,,,,0,0,24503000,0,-10463000,,-34966000,-34966000,12462000.0,414463000.0,150296000.0,-6534000.0,1816000.0,143762000.0,590000.0,1416000.0,-421587000.0,29407000.0,115730000.0,50676000.0,506000.0,130794000.0,99071000.0,46083000.0,34280000.0,,41405000.0,-18000.0,24050000.0,31383000.0,873000.0,2749000.0,11194000.0,-20171000.0,506000.0,-40597000.0,4584000.0,11350000.0,-18000.0,,,15064000.0,en-US,US,EQUITY,False,Delayed Quote,USD,us_market,-0.026,1.4719445,-0.091944456,-0.062464625,2.4202898,-1.0402898,-0.42982033,845767488,-7.6666665,-53.076923,15,America/New_York,EDT,-14400000,False,False,1.38,1630439981,0.049999952,1.28,1.34,1.28,1050119,REGULAR,PNK,4,3.759395,1.28 - 1.34,1.28,0.0,0.0,0,0,finmb_10039157,Other OTC,CytoDyn Inc.,USD,2096629,1783950,0.120000005,0.0952381,1.26 - 7.4,-6.02,-0.8135135,1.26,7.4,-0.294,-0.18,0,CYTODYN INC,-0.56,,,7.4,1.26,1.4719,2.4203,2.1M,1.78M,612.88M,,553.54M,12.75%,0.14%,,,,,,,,,,,0.00%,,,,,"May 30, 2021","May 30, 2021",0.00%,0.00%,-64.72%,,,,,,-92.75M,-154.67M,-0.2940,,33.94M,0.05,63.47M,,0.85,-0.03,-117.57M,-76.66M,Value,98660,Healthcare,24,"CytoDyn Inc. operates as a late-stage biotechnology company. The company focuses on developing treatments for multiple therapeutic indications based on leronlimab, a novel humanized monoclonal antibody targeting the CCR5 receptor. Its Leronlimab is in a class of therapeutic monoclonal antibodies designed to address unmet medical needs in the areas of human immunodeficiency virus (HIV), cancer, immunology, and novel coronavirus disease (COVID-19). The company has completed a Phase 2b pivotal trial using leronlimab in combination with antiretroviral therapies in HIV-infected treatment-experienced patients, as well as completed a Phase 2b/3 investigative trial with leronlimab as a once-weekly monotherapy for HIV-infected patients. It is also conducting a Phase 1b/2 clinical trial with leronlimab in metastatic triple-negative breast cancer. The company was formerly known as RexRay Corporation. CytoDyn Inc. was incorporated in 2002 and is based in Vancouver, Washington.",Vancouver,360 980 8524,WA,1609372800,United States,http://www.cytodyn.com,86400,1111 Main Street,360 799 5954,Biotechnology,Suite 660
t-3,CYDY,-10191000.0,612875008,15188000,,-30832000,,-30832000,9875000,0,-25568000,-25568000,,-5264000,,,,0,0,25568000,0,-5264000,,-30832000,-30832000,12959000.0,388404000.0,90594000.0,2768000.0,1414000.0,93362000.0,570000.0,2374000.0,-386206000.0,18200000.0,76424000.0,18124000.0,527000.0,79876000.0,58474000.0,21351000.0,,13856000.0,20127000.0,-59000.0,25000000.0,44928000.0,199000.0,13508000.0,3921000.0,-40948000.0,505000.0,-39327000.0,7441000.0,7037000.0,-59000.0,-778000.0,-243000.0,3452000.0,en-US,US,EQUITY,False,Delayed Quote,USD,us_market,-0.026,1.4719445,-0.091944456,-0.062464625,2.4202898,-1.0402898,-0.42982033,845767488,-7.6666665,-53.076923,15,America/New_York,EDT,-14400000,False,False,1.38,1630439981,0.049999952,1.28,1.34,1.28,1050119,REGULAR,PNK,4,3.759395,1.28 - 1.34,1.28,0.0,0.0,0,0,finmb_10039157,Other OTC,CytoDyn Inc.,USD,2096629,1783950,0.120000005,0.0952381,1.26 - 7.4,-6.02,-0.8135135,1.26,7.4,-0.294,-0.18,0,CYTODYN INC,-0.56,,,7.4,1.26,1.4719,2.4203,2.1M,1.78M,612.88M,,553.54M,12.75%,0.14%,,,,,,,,,,,0.00%,,,,,"May 30, 2021","May 30, 2021",0.00%,0.00%,-64.72%,,,,,,-92.75M,-154.67M,-0.2940,,33.94M,0.05,63.47M,,0.85,-0.03,-117.57M,-76.66M,Value,98660,Healthcare,24,"CytoDyn Inc. operates as a late-stage biotechnology company. The company focuses on developing treatments for multiple therapeutic indications based on leronlimab, a novel humanized monoclonal antibody targeting the CCR5 receptor. Its Leronlimab is in a class of therapeutic monoclonal antibodies designed to address unmet medical needs in the areas of human immunodeficiency virus (HIV), cancer, immunology, and novel coronavirus disease (COVID-19). The company has completed a Phase 2b pivotal trial using leronlimab in combination with antiretroviral therapies in HIV-infected treatment-experienced patients, as well as completed a Phase 2b/3 investigative trial with leronlimab as a once-weekly monotherapy for HIV-infected patients. It is also conducting a Phase 1b/2 clinical trial with leronlimab in metastatic triple-negative breast cancer. The company was formerly known as RexRay Corporation. CytoDyn Inc. was incorporated in 2002 and is based in Vancouver, Washington.",Vancouver,360 980 8524,WA,1609372800,United States,http://www.cytodyn.com,86400,1111 Main Street,360 799 5954,Biotechnology,Suite 660
